Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis
Recruiting · NCT06477536 · Interventional (participants receive a specific treatment) · Lead sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd.
View the official record on ClinicalTrials.gov →Interventions studied
HB0034
What this trial is about
This is a Phase IIb, long term extension study to evaluate the safety and efficacy of HB0034 in adult subjects with generalized pustular psoriasis (GPP).
Who can take part
Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2, Phase 3
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Patients participated in the preceding placebo-controlled Phase 2 study （HB0034-04）and completed at least the Week 12 visit of the HB0034-04 study
- Subject must be a candidate for prolonged GPP treatment according to the Investigator's judgment
- Men and women of reproductive age who have no parenting plans and are willing to use reliable contraception during the study period and for 6 months after the last dose of the study drug;
- Patients who fully understand and voluntarily sign an ICF, and are willing and able to follow clinical study and subsequent visit schedules
Exclusion criteria
- Patients who are experiencing GPP flare
Where it is running
3 locations listed.
- Peking University People's Hospital (PKUPH) - Beijing, China
- Peking University People's Hospital - Beijing, China
- The Second affiliated Hospital zhejiang University School of Medicine - Hangzhou, China